Spots Global Cancer Trial Database for A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Official Title: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Study ID: NCT03628677
Conditions
Study Description
Brief Summary: This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
Detailed Description: This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies. In this dose escalation study, participants will receive domvanalimab administered intravenously as monotherapy or in combination with zimberelimab. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic and Research Institute, Los Angeles, California, United States
Carolina BioOncology Institute, Huntersville, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
START, San Antonio, Texas, United States
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
Albury, Australia, Albury, New South Wales, Australia
Principal Investigator, Camperdown, New South Wales, Australia
The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
Scientia Clinical Research, Randwick, New South Wales, Australia
Principal Investigator, Tweed Heads, New South Wales, Australia
Principal Investigator, South Brisbane, Queensland, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Contact Details
Name: Medical Director
Affiliation: Arcus Biosciences, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
